Abstract
With the development of mobile communication technology, smartphones have been used in point-of-care technologies (POCTs) as an important part of telemedicine. Using a multidisciplinary design principle coupling electrical engineering, software development, synthetic biology, and optogenetics, the investigators developed a smartphone-controlled semiautomatic theranostic system that regulates blood glucose homeostasis in diabetic mice in an ultraremote-control manner. The present chapter describes how the investigators tailor-designed the implant architecture “HydrogeLED,” which is capable of coharboring a designer-cell-carrying alginate hydrogel and wirelessly powered far-red light LEDs. Using diabetes mellitus as a model disease, the in vivo expression of insulin or human glucagon-like peptide 1 (shGLP-1) from HydrogeLED implants could be controlled not only by pre-set ECNU-TeleMed programs, but also by a custom-engineered Bluetooth-active glucometer in a semiautomatic and glycemia-dependent manner. As a result, blood glucose homeostasis was semiautomatically maintained in diabetic mice through the smartphone-controlled semiautomatic theranostic system. By combining digital signals with optogenetically engineered cells, the present study provides a new method for the integrated diagnosis and treatment of diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhang J, Li Y, Li H et al (2018) GDF11 improves Angiogenic function of EPCs in diabetic limb ischemia. Diabetes 67(10):2084–2095
Saeedi P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes research and clinical practice 157:107843
American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes—2020. Diabetes Care 43(Supplement 1):S14–S31
Yang X, Ongusaha PP, Miles PD et al (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451(7181):964–969
Langlet F, Haeusler RA, Lindén D et al (2017) Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell 171(4):824–835.e818
Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321–1331
Gubitosi-Klug RA, Braffett BH, White NH et al (2017) Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 40(8):1010–1016
Cravalho CK, Meyers AG, Mabundo L et al (2019) 1326-P: metformin increases GLP-1 concentrations and improves glycemia in youth with Type 2 diabetes. Diabetes 68(Supplement 1):1326
Yamaguchi T, Sato H, Kato-Itoh M et al (2017) Interspecies organogenesis generates autologous functional islets. Nature 542(7640):191–196
Zhu Z, Li QV, Lee K et al (2016) Genome editing of lineage determinants in human pluripotent stem cells reveals mechanisms of pancreatic development and diabetes. Cell Stem Cell 18(6):755–768
Zhou Q, Melton DA (2018) Pancreas regeneration. Nature 557(7705):351–358
Smalley E (2016) Medtronic automated insulin delivery device gets FDA nod. Nat Biotechnol 34(12):1220
Knebel T, Neumiller JJ (2019) Medtronic MiniMed 670G hybrid closed-loop system. Clin Diabetes 37(1):94–95
Saunders A, Messer LH, Forlenza GP (2019) MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices 16(10):845–853
Trevitt S, Simpson S, Wood A (2016) Artificial pancreas device Systems for the Closed-Loop Control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 10(3):714–723
Quesada-González D, Merkoçi A (2017) Mobile phone-based biosensing: an emerging “diagnostic and communication” technology. Biosens Bioelectron 92:549–562
Wang P, Kricka LJ (2018) Current and emerging trends in point-of-care technology and strategies for clinical validation and implementation. Clin Chem 64(10):1439–1452
Sharp L, Farrance I, Greaves RF (2016) The application of glucose point of care testing in three metropolitan hospitals. Pathology 48(1):51–59
Shao J, Xue S, Yu G et al (2017) Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice. Sci Transl Med 9(387):eaal2298
Ye H, Daoud-El Baba M, Peng RW et al (2011) A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science (New York, NY) 332(6037):1565–1568
Shao J, Wang M, Yu G et al (2018) Synthetic far-red light-mediated CRISPR-dCas9 device for inducing functional neuronal differentiation. Proc Natl Acad Sci U S A 115(29):E6722–E6730
Acknowledgments
We are very grateful to Dr. Ningzi Guan for revising the manuscript. This work was financially supported by the grants from the National Key R&D Program of China, Synthetic Biology Research (no. 2019YFA0904500), the National Natural Science Foundation of China (NSFC: no. 31971346, no. 31861143016), the Science and Technology Commission of Shanghai Municipality (no. 18JC1411000) to H.Y. Materials availability: All genetic components related to this paper are available with a material transfer agreement and can be requested from H.Y. (hfye@bio.ecnu.edu.cn).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yu, G., Yu, Y., Ye, H. (2021). Constructing a Smartphone-Controlled Semiautomatic Theranostic System for Glucose Homeostasis in Diabetic Mice. In: Kojima, R. (eds) Mammalian Cell Engineering. Methods in Molecular Biology, vol 2312. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1441-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1441-9_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1440-2
Online ISBN: 978-1-0716-1441-9
eBook Packages: Springer Protocols